HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer’s disease in a three cohorts study

Several retrospective epidemiological studies report that utilization of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) inhibitors called statins at mid-life can reduce the risk of developing sporadic Alzheimer’s disease (AD) by as much as 70%. Conversely, administration of these inhibitors in cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Leduc, Valerie, De Beaumont, Louis, Théroux, Louise, Dea, Doris, Aisen, Paul, Petersen, Ronald C., Dufour, Robert, Poirier, Judes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318698/
https://www.ncbi.nlm.nih.gov/pubmed/25023145
http://dx.doi.org/10.1038/mp.2014.81

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318698/
https://www.ncbi.nlm.nih.gov/pubmed/25023145
http://dx.doi.org/10.1038/mp.2014.81

Ejemplares similares